Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
17.71
+0.68 (3.99%)
At close: Apr 15, 2025, 4:00 PM
17.56
-0.15 (-0.84%)
After-hours: Apr 15, 2025, 6:26 PM EDT
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Tandem Diabetes Care stock have an average target of 44.44, with a low estimate of 20 and a high estimate of 75. The average target predicts an increase of 150.93% from the current stock price of 17.71.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tandem Diabetes Care stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
Buy | 7 | 8 | 8 | 8 | 6 | 6 |
Hold | 4 | 3 | 3 | 2 | 5 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 16 | 16 | 16 | 15 | 15 | 16 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Mizuho | Mizuho | Hold Initiates $20 | Hold | Initiates | $20 | +12.93% | Apr 10, 2025 |
Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $45 → $22 | Buy → Hold | Downgrades | $45 → $22 | +24.22% | Mar 5, 2025 |
Citigroup | Citigroup | Strong Buy → Hold Downgrades $35 → $24 | Strong Buy → Hold | Downgrades | $35 → $24 | +35.52% | Mar 4, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $42 → $24 | Hold | Maintains | $42 → $24 | +35.52% | Mar 3, 2025 |
Wells Fargo | Wells Fargo | Buy → Hold Downgrades $38 → $22 | Buy → Hold | Downgrades | $38 → $22 | +24.22% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
1.02B
from 940.20M
Increased by 8.59%
Revenue Next Year
1.13B
from 1.02B
Increased by 10.97%
EPS This Year
-1.28
from -1.47
EPS Next Year
-0.71
from -1.28
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 1.1B | 1.2B | 1.3B | ||
Avg | 1.0B | 1.1B | 1.2B | ||
Low | 965.7M | 1.1B | 1.1B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 14.8% | 18.5% | 17.6% | ||
Avg | 8.6% | 11.0% | 9.7% | ||
Low | 2.7% | 3.7% | -0.3% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.06 | -0.45 | 0.92 | ||
Avg | -1.28 | -0.71 | -0.18 | ||
Low | -1.41 | -0.97 | -0.66 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.